Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

55%

11 trials in Phase 3/4

Results Transparency

12%

2 of 17 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
10(50.0%)
N/A
5(25.0%)
Phase 2
4(20.0%)
Phase 4
1(5.0%)
20Total
Phase 3(10)
N/A(5)
Phase 2(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT05144217Phase 2Completed

Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo

Role: collaborator

NCT04448808Phase 2Completed

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol

Role: collaborator

NCT06211049Phase 3Completed

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Role: lead

NCT03984214Phase 3Completed

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Role: collaborator

NCT05276375Phase 2Completed

Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19

Role: collaborator

NCT04147273Not ApplicableCompleted

Determination of Postprandial Glycemic Responses by Continuous Glucose Monitoring in a Real-World Setting

Role: collaborator

NCT05807113Not ApplicableCompleted

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis

Role: lead

NCT05790083Not ApplicableUnknown

Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema

Role: lead

NCT05786976Not ApplicableCompleted

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis

Role: lead

NCT03756974Phase 3Completed

BX-1 in Spasticity Due to Multiple Sclerosis

Role: lead

NCT04537819Not ApplicableCompleted

Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis

Role: collaborator

NCT04498013Phase 4Unknown

Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52

Role: collaborator

NCT01478620Phase 3Completed

Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)

Role: lead

NCT02746042Phase 3Completed

Sinupret Extract Coated Tablets in Chronic Rhinosinusitis

Role: lead

NCT02639520Phase 3Completed

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Role: lead

NCT01870687Phase 3Terminated

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Role: lead

NCT01706484Phase 3Completed

Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

Role: lead

NCT01928901Phase 2Completed

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Role: lead

NCT01146860Phase 3Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Role: lead

NCT01309113Phase 3Completed

Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome

Role: lead

All 20 trials loaded